Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02486718
Registration number
NCT02486718
Ethics application status
Date submitted
4/06/2015
Date registered
1/07/2015
Date last updated
11/07/2025
Titles & IDs
Public title
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Query!
Scientific title
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Query!
Secondary ID [1]
0
0
2014-003205-15
Query!
Secondary ID [2]
0
0
GO29527
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Cisplatin
Treatment: Drugs - Vinorelbine
Treatment: Drugs - Docetaxel
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Pemetrexed
Experimental: Atezolizumab - Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
Active comparator: Best Supportive Care - Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
Treatment: Drugs: Atezolizumab
Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
Treatment: Drugs: Cisplatin
Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Treatment: Drugs: Vinorelbine
Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Treatment: Drugs: Docetaxel
Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Treatment: Drugs: Gemcitabine
Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Treatment: Drugs: Pemetrexed
Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population
Query!
Assessment method [1]
0
0
DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.
Query!
Timepoint [1]
0
0
Up to 95 months
Query!
Primary outcome [2]
0
0
DFS in All Randomized Stage II-IIIA Population
Query!
Assessment method [2]
0
0
DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in participants with disease stage II-IIIA. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.
Query!
Timepoint [2]
0
0
Up to 95 months
Query!
Primary outcome [3]
0
0
DFS in the Programmed Death-ligand 1 (PD-L1) SP263 = 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population
Query!
Assessment method [3]
0
0
DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 =1% subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.
Query!
Timepoint [3]
0
0
Up to 95 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS) in the ITT Population
Query!
Assessment method [1]
0
0
OS was defined as the time from randomization to death from any cause.
Query!
Timepoint [1]
0
0
Up to 20 years
Query!
Secondary outcome [2]
0
0
Disease-free Rate at Year 3 in ITT Population
Query!
Assessment method [2]
0
0
DFS rate was defined as percentage of participants who were disease-free at Year 3. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.
Query!
Timepoint [2]
0
0
Year 3
Query!
Secondary outcome [3]
0
0
Disease-free Rate at Year 3 in All Randomized Stage II-IIIA Population
Query!
Assessment method [3]
0
0
DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.
Query!
Timepoint [3]
0
0
Year 3
Query!
Secondary outcome [4]
0
0
Disease-free Rate at Year 3 in PD-L1 (SP263 = 1% TC) Subpopulation Within the Stage II-IIIA Population
Query!
Assessment method [4]
0
0
DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.
Query!
Timepoint [4]
0
0
Year 3
Query!
Secondary outcome [5]
0
0
Disease-free Rate at Year 5 in ITT Population
Query!
Assessment method [5]
0
0
DFS rate was defined as percentage of participants who were disease-free at Year 5. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.
Query!
Timepoint [5]
0
0
Year 5
Query!
Secondary outcome [6]
0
0
Disease-free Rate at Year 5 in All Randomized Stage II-IIIA Population
Query!
Assessment method [6]
0
0
DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.
Query!
Timepoint [6]
0
0
Year 5
Query!
Secondary outcome [7]
0
0
Disease-free Rate at Year 5 in PD-L1 (SP263 = 1% TC) Subpopulation Within the Stage II-IIIA Population
Query!
Assessment method [7]
0
0
DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.
Query!
Timepoint [7]
0
0
Year 5
Query!
Secondary outcome [8]
0
0
DFS in the PD-L1 (SP263 = 50% TC) Subpopulation Within the Stage II-IIIA Population
Query!
Assessment method [8]
0
0
DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.
Query!
Timepoint [8]
0
0
Up to 95 months
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Adverse Events (AEs)
Query!
Assessment method [9]
0
0
An AE is any untoward medical occurrence in a participant when administered a pharmaceutical product regardless of the causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.
Query!
Timepoint [9]
0
0
Up to 20 years
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Query!
Assessment method [10]
0
0
The percentage of ATA (Also called anti-drug antibodies (ADA))-positive participants after drug administration were determined for participants exposed to atezolizumab. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.
Query!
Timepoint [10]
0
0
Predose (Hour 0) on Day 1 of Cycles 2, 3, 4, 8, 16 (Cycle length = 21 days), at treatment discontinuation (TD) (up to 12 months), 120 days after last atezolizumab administration (up to 16 months)
Query!
Secondary outcome [11]
0
0
Maximum Plasma Concentration (Cmax) of Atezolizumab
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
30 min post-infusion on Day 1 of Cycle 1 (Cycle length = 21 days)
Query!
Secondary outcome [12]
0
0
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Prior to infusion on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (Cycle length = 21 days), at study discontinuation visit (up to 12 months), Day 120 post last dose of atezolizumab (up to 16 months)
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria for Enrollment Phase
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Histological or cytological diagnosis of Stage IB (tumors greater than or equal to [>/=] 4 centimeters [cm])-IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) NSCLC (per the Union Internationale Contre le Cancer staging system (UICC)/American Joint Committee on Cancer staging system (AJCC) staging system, 7th edition; Detterbeck et al. 2009)
* Participants must have had complete resection of NSCLC 4-12 weeks (>/=28 days and less than or equal to [</=] 84 days) prior to enrollment and must be adequately recovered from surgery
* If mediastinoscopy was not performed preoperatively, it is required that, at a minimum, mediastinal lymph node systematic sampling will have occurred. Systematic sampling is defined as removal of at least one representative lymph node at specified levels. MLND entails resection of all lymph nodes at those same levels. For a right thoracotomy, sampling or MLND is required at levels 4 and 7 and for a left thoracotomy, levels 5 and/or 6 and 7. Exceptions will be granted if there is clear documentation in the operative report or in a separately submitted addendum by the surgeon of exploration of the required lymph node areas, the participant will be considered eligible if no lymph nodes are found in those areas; if participants have documented N2 disease in one level (per the UICC/AJCC staging system, 7th edition; Detterbeck et al. 2009), not all levels need to be sampled; if the preoperative staging imaging results (contrast computed tomography [CT] and positron emission tomography [PET] scans) do not suggest evidence of disease in the mediastinum, the participant will be considered eligible if N2 nodal sampling is not performed per surgeon's decision
* Eligible to receive a cisplatin-based chemotherapy regimen
* Adequate hematologic and end-organ function
* Women who are not postmenopausal (>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of cisplatin-based chemotherapy
Inclusion Criteria for Randomized Phase - Women who are not postmenopausal (>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of atezolizumab or BSC
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria for Enrollment Phase
* Illness or condition that may interfere with a participant's capacity to understand, follow, and/or comply with study procedures
* Pregnant and lactating women
* Treatment with prior systemic chemotherapy: Chemotherapy for early stage of malignancy with curative intent, provided that the last dose received was more than 5 years prior to enrollment and low-dose chemotherapy for non-malignant conditions may be allowed upon approval by the Medical Monitor
* Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years before enrollment
* Treatment with any other investigational agent with therapeutic intent within 28 days prior to enrollment
* Participants with hearing impairment
* Known sensitivity to any component of the chemotherapy regimen the participant will be assigned to, or to mannitol
* Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti programmed death ligand 1 (PD-L1) therapeutic antibodies
* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS greater than [>] 90 percent [%]) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
* History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
* Positive test for human immunodeficiency virus (HIV)
* Participants with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
* Active tuberculosis
* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within the previous 3 months, unstable arrhythmias, or unstable angina
* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
* Prior allogeneic bone marrow transplantation or solid organ transplant
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
* Known tumor PD-L1 expression status as determined by an immunohistochemistry (IHC) assay from other clinical studies (e.g., participants whose PD-L1 expression status was determined during screening for entry into a study with anti-PD-1 or anti-PD-L1 antibodies but were not eligible are excluded)
Specific Exclusions for Pemetrexed Treatment
- Participants with squamous cell histology
Exclusion Criteria for Randomized Phase
* Signs or symptoms of infection within 14 days prior to randomization (severe infection within 28 days prior to randomization), including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
* Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to randomization
* Major surgical procedure within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
* Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live attenuated vaccine will be required during the study
* Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to randomization: Prior treatment with cancer vaccines is allowed
* Treatment with systemic corticosteroids or other immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/10/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/08/2035
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1280
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Townsville Hospital - Douglas
Query!
Recruitment hospital [2]
0
0
Cabrini Hospital Malvern - Malvern
Query!
Recruitment postcode(s) [1]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [2]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Jersey
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bruxelles
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Beijing
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Guangzhou City
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Hangzhou
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Hefei
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Shanghai
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Shengyang
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Shenyang
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Suzhou
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Mont de Marsan
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Montpellier
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Nantes
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Saint Pierre
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Saint-Quentin
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Toulon
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Berlin
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Bielefeld
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Braunschweig
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Chemnitz
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Frankfurt am Main
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Großhansdorf
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Hemer
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Homburg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Immenhausen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Karlsruhe
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Koblenz Am Rhein
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
München
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Münster
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Oldenburg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Regensburg
Query!
Country [48]
0
0
Hong Kong
Query!
State/province [48]
0
0
Shatin
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Pecs
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Szolnok
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Haifa
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Holon
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Kfar Saba
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Tel Hashomer
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Tel-Aviv
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Abruzzo
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Friuli-Venezia Giulia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Lazio
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Lombardia
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Piemonte
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Sicilia
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Toscana
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Trentino-Alto Adige
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Umbria
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Veneto
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Aichi
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Akashi
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Bunkyo-ku
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Chuo
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Fukuoka
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Hiroshima
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Kitaadachi-gun
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Kitakyushu-shi
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Kumamoto-shi
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Kyoto
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Matsuyama-shi
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Mitaka-shi
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Niigata-shi
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Okayama
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Sapporo-shi
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Tokyo
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Yokohama-shi, Asahi-ku
Query!
Country [83]
0
0
Korea, Republic of
Query!
State/province [83]
0
0
Jeonnam
Query!
Country [84]
0
0
Korea, Republic of
Query!
State/province [84]
0
0
Suwon-si,
Query!
Country [85]
0
0
Netherlands
Query!
State/province [85]
0
0
Noord-Brabant
Query!
Country [86]
0
0
Netherlands
Query!
State/province [86]
0
0
Nieuwegein
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Otwock
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Poznan
Query!
Country [89]
0
0
Portugal
Query!
State/province [89]
0
0
Coimbra
Query!
Country [90]
0
0
Portugal
Query!
State/province [90]
0
0
Porto
Query!
Country [91]
0
0
Romania
Query!
State/province [91]
0
0
Craiova
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Moskovskaja Oblast
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Sankt Petersburg
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Novosibirsk
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Volgograd
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Yaroslavl
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Cantabria
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Castellon
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Murcia
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Tenerife
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Barcelona
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Cordoba
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Jaen
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Lugo
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Madrid
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Valencia
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Zaragoza
Query!
Country [108]
0
0
Taiwan
Query!
State/province [108]
0
0
Changhua
Query!
Country [109]
0
0
Taiwan
Query!
State/province [109]
0
0
Putzui City
Query!
Country [110]
0
0
Taiwan
Query!
State/province [110]
0
0
Taichung
Query!
Country [111]
0
0
Taiwan
Query!
State/province [111]
0
0
Taipei
Query!
Country [112]
0
0
Taiwan
Query!
State/province [112]
0
0
Taoyuan City
Query!
Country [113]
0
0
Ukraine
Query!
State/province [113]
0
0
Katerynoslav Governorate
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Kharkiv Governorate
Query!
Country [115]
0
0
Ukraine
Query!
State/province [115]
0
0
KIEV Governorate
Query!
Country [116]
0
0
Ukraine
Query!
State/province [116]
0
0
Poltava Governorate
Query!
Country [117]
0
0
Ukraine
Query!
State/province [117]
0
0
Vinnyts'ka Oblast
Query!
Country [118]
0
0
Ukraine
Query!
State/province [118]
0
0
Kryvyi Rih
Query!
Country [119]
0
0
Ukraine
Query!
State/province [119]
0
0
Kyiv
Query!
Country [120]
0
0
Ukraine
Query!
State/province [120]
0
0
Sumy
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Zaporizhzhya
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Colchester, Essex
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02486718
Query!
Trial related presentations / publications
Mohindra NA, Patel JD. Top advances in lung cancer, 2021. Cancer. 2022 Oct 1;128(19):3434-3437. doi: 10.1002/cncr.34406. Epub 2022 Aug 10. Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/18/NCT02486718/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/18/NCT02486718/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02486718
Download to PDF